JP2020517272A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517272A5
JP2020517272A5 JP2019557431A JP2019557431A JP2020517272A5 JP 2020517272 A5 JP2020517272 A5 JP 2020517272A5 JP 2019557431 A JP2019557431 A JP 2019557431A JP 2019557431 A JP2019557431 A JP 2019557431A JP 2020517272 A5 JP2020517272 A5 JP 2020517272A5
Authority
JP
Japan
Prior art keywords
recombinant phagemid
genome
particle
particles
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019557431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517272A (ja
JP7671483B2 (ja
Filing date
Publication date
Priority claimed from GBGB1706451.0A external-priority patent/GB201706451D0/en
Application filed filed Critical
Publication of JP2020517272A publication Critical patent/JP2020517272A/ja
Publication of JP2020517272A5 publication Critical patent/JP2020517272A5/ja
Application granted granted Critical
Publication of JP7671483B2 publication Critical patent/JP7671483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019557431A 2017-04-24 2018-04-24 癌の治療 Active JP7671483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1706451.0 2017-04-24
GBGB1706451.0A GB201706451D0 (en) 2017-04-24 2017-04-24 Cancer treatment
PCT/GB2018/051070 WO2018197859A1 (en) 2017-04-24 2018-04-24 Cancer treatment

Publications (3)

Publication Number Publication Date
JP2020517272A JP2020517272A (ja) 2020-06-18
JP2020517272A5 true JP2020517272A5 (enExample) 2021-07-29
JP7671483B2 JP7671483B2 (ja) 2025-05-02

Family

ID=58795775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557431A Active JP7671483B2 (ja) 2017-04-24 2018-04-24 癌の治療

Country Status (7)

Country Link
US (2) US11820792B2 (enExample)
EP (1) EP3615562A1 (enExample)
JP (1) JP7671483B2 (enExample)
CN (1) CN110546253A (enExample)
CA (1) CA3061422A1 (enExample)
GB (1) GB201706451D0 (enExample)
WO (1) WO2018197859A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment
CN110662834B (zh) 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
EP3892721A4 (en) * 2018-11-14 2022-08-31 GC Cell Corporation METHOD FOR CULTIVATING NATURAL KILLER CELLS DERIVED FROM UMBILICAL CORD BLOOD USING TRANSFORMED T LYMPHOCYTES
WO2022272297A1 (en) * 2021-06-25 2022-12-29 Oxford Biomedica Solutions Llc Adeno-associated virus packaging systems
WO2024149989A1 (en) * 2023-01-10 2024-07-18 Imperial College Innovations Limited Phage vector
CN116790520A (zh) * 2023-06-20 2023-09-22 扬州大学 一种可识别肿瘤表面的cea蛋白与表达3c蛋白的短链噬菌粒及其构建与应用
CN116790521A (zh) * 2023-06-20 2023-09-22 扬州大学 一种可识别肿瘤表面的cea蛋白与表达egfp蛋白的重组噬菌体及其构建与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP1660636A4 (en) 2003-08-26 2009-07-01 Univ Texas VACCINES AGAINST CANCER
EP1960526A4 (en) 2005-12-07 2009-07-15 Los Alamos Nat Security Llc PLASMIDES AND PACKAGING CELL LINES FOR USE IN A PHAG DISPLAY
EP2009990B1 (en) 2006-04-07 2016-09-21 The Board of Regents of The University of Texas System Methods and compositions related to adenoassociated virus-phage particles
JP2013527753A (ja) * 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
GB201308742D0 (en) 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
GB201308745D0 (en) 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
WO2015105806A2 (en) * 2014-01-07 2015-07-16 Oklahoma Medical Research Foundation Antibodies against glioma biomarkers
AU2016334401A1 (en) * 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
GB201519303D0 (en) 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment

Similar Documents

Publication Publication Date Title
JP2020517272A5 (enExample)
US20220378822A1 (en) Combinatorial cancer immunotherapy
US11596685B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
JP2020011966A (ja) 増強された養子細胞療法
JP2023524061A (ja) 操作された中枢神経系用組成物
Ruiz et al. MicroRNA-detargeted mengovirus for oncolytic virotherapy
JP2019501661A5 (enExample)
JP2018533949A5 (enExample)
WO2018228538A1 (zh) 重组单纯疱疹病毒及其制备方法和应用
US20200017881A1 (en) Programmable Oncolytic Virus Vaccine System and Method
US20250059564A1 (en) Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
CN102260712B (zh) 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
CN104212802A (zh) 一种肿瘤细胞广谱高活性启动子及其用途
CA3110282A1 (en) Fasl immunomodulatory gene therapy compositions and methods for use
JP2021500070A5 (enExample)
CN102985094B (zh) 一种重组肿瘤疫苗及其生产方法
Kobelt et al. A brief introduction to current cancer gene therapy
Goding et al. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells
TW202448922A (zh) 改良之ert2突變體、可誘導型細胞死亡系統及其用途
CN120513099A (zh) 巨噬细胞特异性启动子和其用途
CN112011570A (zh) 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
CN119585419A (zh) 工程化t细胞
EP3822355A1 (en) Anti-tumor composition
CN112823209A (zh) 使用编码高度紧凑的多输入逻辑门的核酸载体治疗疾病的方法
AU2025271119A1 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids